Cure8 research brief
Filgotinib (a JAK inhibitor) is presented as an effective option for inducing rapid symptom relief and maintaining remission in ulcerative colitis, which could expand treatment choices for people with UC, including those seeking steroid-sparing long-term control.
Adult patients with ulcerative colitis, clinicians treating UC, patients on or considering advanced therapies (biologics/JAK inhibitors), and researchers of IBD therapeutics.
The article focuses on filgotinib, a JAK inhibitor, and reports symptom relief (including improvements in rectal bleeding and stool frequency) within about a week and sustained clinical remission and Mayo score responses up to 4 years in trial and long-term-extension data.
The 200 mg dose generally showed greater efficacy than 100 mg, and some analyses suggest biologic-naive patients may achieve larger sustained gains. Safety findings in the cited trials and extensions did not identify unexpected signals.
The article is a narrative review (abstract-level content provided) summarizing trial and real-world evidence; it is not a primary randomized-trial report. Filgotinib dosing comparisons (100 mg vs 200 mg) and subgroup observations (biologic-naive vs experienced) are from included studies and may require direct trial review for decision-making.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...
